CG Oncology, Inc. Common stock (CGON) is a Biotechnology company in the Healthcare sector, currently trading at $67.28. It has a SharesGrow Score of 45/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is CGON = $79 (+17.4% upside).
Valuation: CGON trades at a trailing Price-to-Earnings (P/E) of -32.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 2.04.
Financials: revenue is $4M, +239.9%/yr average growth. Net income is $161M (loss), growing at -67%/yr. Net profit margin is -3985% (negative). Gross margin is -15% (-107.1 pp trend).
Balance sheet: total debt is $7M against $753M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 24.63 (strong liquidity). Debt-to-assets is 0.9%. Total assets: $792M.
Analyst outlook: 9 / 9 analysts rate CGON as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 41/100 (Partial), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 12/100 (Fail), Future 94/100 (Pass), Income 10/100 (Fail).
